NCT05560776

Optimizing Endobronchial Ultrasound Sampling for Molecular Markers for NSCLC

OPTimizing Endobronchial Ultrasound Sampling In Suspected Non Small Cell Lung Cancer for Molecular Markers : A Pragmatic Randomized Controlled TriaL

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this monocentric randomized controlled trial, 120 potential non small cell lung cancer (NSCLC) patients for which tissue diagnosis and material for next generation sequencing (NGS) is required for clinical management will be approached the day of their endobronchial ultrasound to participate in the study. They will be randomized to 2 vs 3 passes/lymph node and will all undergo liquid biopsy. The co-primary outcomes are 1)the rate of obtention of adequate material for NGS testing with 2 vs 3 passes/lymph node and 2)the percentage of patients for which liquid biopsy allows to identify clinically pertinent findings not available from tissue biopsy

Conditions

• Lung Cancer
• Non Small Cell Lung Cancer
• Circulating Tumor Cell

Interventions

Type	Name	Description
PROCEDURE	Endobronchial ultrasound	Two or three passes per lymph node

Timeline

• Start date: 2023-05-01
• Primary completion: 2026-05-01
• Completion: 2026-05-01
• First posted: 2022-09-29
• Last updated: 2026-01-26

Locations

1 site across 1 country: Canada